SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
830.00    14.00 (1.72%)
Bid:
824.00
Ask:
828.00
Spread: 4.00 (0.485%)
Market Cap: £382.60m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Board Changes

25 Sep 2025 07:00

RNS Number : 6929A
Porvair PLC
25 September 2025
 

 

For immediate release 25 September 2025

 

 

Porvair plc

("Porvair" or the "Group" or the "Company")

 

Board Changes

Lisa Anson

Lisa Anson has been appointed as Non-Executive Director of the Company with effect from 1 October 2025.

Lisa is currently Chief Executive Officer of Redx Pharma limited, a UK based, privately held clinical-stage biotech business; a position she held when Redx was publicly listed on AIM. In addition, she is a Supervisory Board Member for Apoplex Medical Technologies GmBH, a private German company and is an elected Board Member of the UK BioIndustry Association (BIA). She was previously a Board Member and then Chair at the Association of the British Pharmaceutical Industry (ABPI).

Lisa's career spans almost 30 years in the pharmaceutical and Biotech industry including more than twenty years at AstraZeneca Plc. She has extensive global leadership and commercial experience, including several USA based roles and most recently was Country President for the UK and Ireland.

On appointment, Lisa will join the Audit Committee, Remuneration Committee and Nomination Committee of Porvair.

Porvair confirms that there are no further matters in relation to Lisa Anson's appointment to be disclosed pursuant to the requirements of paragraph 6.4.8 of the Listing Rules of the UK Listing Authority.

Sally Martin

Having completed 9 years as a Non-Executive Director at Porvair, Sally Martin will retire from the Board on 4 November 2025.

Sheena Mackay

Following Sally's retirement, Sheena Mackay will be appointed Senior Independent Director of the Board and the Non-Executive Director responsible for employee engagement, in addition to her role as Chair of the Remuneration Committee.

For further information, please contact:

Porvair plc

+44 (0)1553 765 500

Hooman Caman Javvi, Chief Executive Officer

Andrew Douglass, Group Company Secretary

 

Burson Buchanan

+44 (0)207 466 5000

Charles Ryland / Stephanie Whitmore

 

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration, laboratory and environmental technology businesses. Its businesses design and manufacture a range of bespoke consumable filtration products that are used in a range of niche filtration markets. It operates in three divisions: Aerospace & Industrial; Laboratory; and Metal Melt Quality.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEZLFLEKLZBBF
Date   Source Headline
1st Mar 20239:30 amRNSTotal Voting Rights
2nd Feb 20235:42 pmRNSGrant of LTSP awards
30th Jan 20237:00 amRNSResults for the year ended 30 November 2022
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSTrading Update, Notice of Results and Board Change
1st Dec 20224:00 pmRNSDirector/PDMR Shareholding
1st Dec 202210:00 amRNSTotal Voting Rights
29th Nov 20224:35 pmRNSPrice Monitoring Extension
1st Nov 20224:00 pmRNSBlock listing Interim Review
1st Nov 20227:00 amRNSTotal Voting Rights
27th Oct 20229:30 amRNSDirector declaration and resignation
12th Oct 20224:26 pmRNSDirector/PDMR Shareholding
5th Oct 20225:30 pmRNSHolding(s) in Company
5th Oct 20225:30 pmRNSHolding(s) in Company
4th Oct 20227:00 amRNSTrading Update-Ahead of Expectations
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
20th Sep 20224:41 pmRNSSecond Price Monitoring Extn
20th Sep 20224:36 pmRNSPrice Monitoring Extension
13th Sep 20227:00 amRNSNine Month Trading Update
9th Sep 20224:40 pmRNSSecond Price Monitoring Extn
9th Sep 20224:35 pmRNSPrice Monitoring Extension
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20226:05 pmRNSDirector/PDMR Shareholding
6th Sep 20224:40 pmRNSHolding(s) in Company
2nd Sep 20223:06 pmRNSHolding(s) in Company
10th Aug 20224:40 pmRNSSecond Price Monitoring Extn
10th Aug 20224:36 pmRNSPrice Monitoring Extension
9th Aug 20224:36 pmRNSPrice Monitoring Extension
8th Jul 20227:00 amRNSDirector Declaration
5th Jul 20224:35 pmRNSPrice Monitoring Extension
4th Jul 20227:00 amRNSHalf Year Results 2022
30th Jun 20222:15 pmRNSDirector/PDMR Shareholding
29th Apr 20224:41 pmRNSSecond Price Monitoring Extn
29th Apr 20224:36 pmRNSPrice Monitoring Extension
28th Apr 20227:00 amRNSDirector/PDMR Shareholding
14th Apr 20221:42 pmRNSAGM resolutions
14th Apr 20227:00 amRNSAGM Trading Update
11th Mar 20224:41 pmRNSSecond Price Monitoring Extn
11th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20224:35 pmRNSPrice Monitoring Extension
28th Feb 20227:00 amRNSBlock listing Interim Review
28th Feb 20227:00 amRNSTotal Voting Rights
4th Feb 20223:00 pmRNSDirector/PDMR Shareholding
4th Feb 202212:20 pmRNSGrant of LTSP awards
3rd Feb 202211:27 amRNSDirector/PDMR Shareholding
31st Jan 20227:00 amRNSResults for the year ended 30 November 2021
14th Dec 202112:25 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.